Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Lorenzo-Zuñiga, V. (V.) | - |
dc.creator | Rodriguez-Ortigosa, C.M. (Carlos M.) | - |
dc.creator | Bartoli, R. (R.) | - |
dc.creator | Martinez-Chantar, M.L. (María Luz) | - |
dc.creator | Martinez-Peralta, L. (L.) | - |
dc.creator | Pardo, A. (A.) | - |
dc.creator | Ojanguren, I. (I.) | - |
dc.creator | Quiroga, J. (Jorge) | - |
dc.creator | Planas, R. (R.) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.date.accessioned | 2012-10-03T08:57:59Z | - |
dc.date.available | 2012-10-03T08:57:59Z | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Lorenzo-Zuniga V, Rodriguez-Ortigosa CM, Bartoli R, Martinez-Chantar ML, Martinez-Peralta L, Pardo A, et al. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006 Sep;55(9):1306-1312. | es_ES |
dc.identifier.issn | 1468-3288 | - |
dc.identifier.uri | https://hdl.handle.net/10171/23286 | - |
dc.description.abstract | BACKGROUND AND AIMS: In liver cirrhosis, disruption of the intestinal barrier facilitates bacterial translocation and spontaneous bacterial peritonitis. Insulin-like growth factor I (IGF-I) is an anabolic hormone synthesised by hepatocytes that displays hepatoprotective activities and trophic effects on the intestine. The aim of this study was to investigate the effect of IGF-I on intestinal barrier function in cirrhotic rats. METHODS: In rats with carbon tetrachloride induced cirrhosis, we investigated the effect of IGF-I therapy on: (a) portal pressure; (b) intestinal histology and permeability to endotoxin and bacteria; (c) intestinal expression of cyclooxygenase 2 (COX-2) and tumour necrosis factor alpha (TNF-alpha), two factors that influence in a positive and negative manner, respectively, the integrity of the intestinal barrier; (d) intestinal permeability to 3H-mannitol in rats with bile duct ligation (BDL); and (e) transepithelial electrical resistance (TER) of polarised monolayers of rat small intestine epithelial cells. RESULTS: IGF-I therapy reduced liver collagen expression and portal pressure in cirrhotic rats, induced improvement in intestinal histology, and caused a reduction in bacterial translocation and endotoxaemia. These changes were associated with diminished TNF-alpha expression and elevated COX-2 levels in the intestine. IGF-I reduced intestinal permeability in BDL rats and enhanced barrier function of the monolayers of epithelial intestinal cells where lipopolysaccharide (LPS) caused a decrease in TER that was reversed by IGF-I. This effect of IGF-I was associated with upregulation of COX-2 in LPS treated enterocytes. CONCLUSIONS: IGF-I enhances intestinal barrier function and reduces endotoxaemia and bacterial translocation in cirrhotic rats. IGF-I therapy might be useful in the prevention of spontaneous bacterial peritonitis in liver cirrhosis. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMJ Publishing Group | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Insulin-Like Growth Factor I/therapeutic use | es_ES |
dc.subject | Intestinal Absorption/drug effects | es_ES |
dc.subject | Liver Cirrhosis, Experimental/drug therapy | es_ES |
dc.title | Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://gut.bmj.com/content/55/9/1306 | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.